Effect of ritonavir on the pharmacodynamics of gliclazide in animal models

Diabetologia Croatica

Volumn 38, Issue 4, 2009, Pages 105-113

  Mastan, Shaik ^a,b   Kumar, Kilari Eswar ^b  

^a JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY   (India)

^b ANDHRA UNIVERSITY   (India)

Author keywords

Diabetes; Gliclazide; HIV infection; Hypoglycemia; Ritonavir

Indexed keywords

ANTIDIABETIC AGENT; GLICLAZIDE; GLUCOSE; INSULIN; RITONAVIR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HYPOGLYCEMIA; MALE; NONHUMAN; PHARMACODYNAMICS; RABBIT; RADIOIMMUNOASSAY; RAT;

EID: 74549132629     PISSN: 03510042     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Satnarayana S, Kilari EK. Influence of nicorandil on the pharmacodynamics and pharmacokinetics of gliclazide in rats and rabbits. Mol Cell Biochem 2006;291:101-105.
2. Saely CH, Aczel S, Marte T. Cardiovascular complications in type 2 diabetes mellitus depend on the coronary angiographic state rather than on the diabetes state. Diabetologia 2004;47:145-146.
3. King H, Aubert RE, Heiman WH. Prevalence: numerical estimates and projections. Global burden of diabetes, 1995-2025. Diabetes Care 1998;21:1414-1431.
4. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey 1988-1994. Diabetes Care 1998;21:518-524.
5. Hruz PW. Molecular mechanisms for altered glucose homeostasis in HIV infection. Am J Infect Dis 2006;2:187-192.
6. Dube MP. Disorders of glucose metabolism in patients infected with human immunodeficiency virus. Clin Infect Dis 2000;31:1467-1475.
7. Zimmet P, Alberti KGMM, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001;141:782-787.
8. Mathias AA, West S, Hui J, Kearney BP. Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure. Clin Pharmacol Ther 2009;85:64-70.
9. Moyle GJ, Back D. Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Medicine 2001;2:105-113.
10. Mastan SK, Chaitanya G, Reddy KR, Kumar KE. An appraisal to the special sulphonylurea: gliclazide. Pharmacologyonline 2009;1:254-269.
11. Brien RC, Luo M, Balazs N, Mercuri J. In vitro and in vivo antioxidant properties of gliclazide. J Diabetes Complications 2000;14:201-206.
12. Homes B, Heel RC, Brogden RN, Speight TM, Avery GS. Gliclazide - a preliminary review of its pharmacodynamic properties and therapeutic efficacy in diabetes mellitus. Drugs 1984;27:301-327.
13. Hsu A, Granneman GR, Bertz RJ. Ritonavir. Clinical pharmacokinetics and interaction with other HIV-agents. Clin Pharmacokinet 1998;35:275-291.
14. Lawrence DR, Bacharach AL, eds. Evaluation of drug activities: pharmacometrics. Vol. I. New York: Academic Press, 1964.
15. Yamaji H, Matsumura Y, Yashikawa Y, Takada K. Pharmacokinetic interactions between HIV-protease inhibitors in rats. Biopharm Drug Dispos 1999;20:241-247.
16. Heikkila RE. The prevention of alloxan-induced diabetes in mice by dimethyl sulfoxide. Eur J Pharmacol 1977;44:191-193.
17. Riley V. Adaptation of orbital bleeding technique to rapid serial blood studies. Proc Soc Exp Biol Med 1960;104:751-754.
18. Trinder P. Determination of blood glucose using an oxidase-peroxidase system with a non carcinogenic chemogen. Clin Pathol 1969;22:158-161.
19. Shalam MD, Harish MS, Farhana SA. Prevention of dextramethasone- and fructose-induced insulin resistance in rats by SH-01D, a herbal preparation. Ind J Pharmacol 2006;38:419-422.
20. Eswar Kumar K, Ramesh A, Satyanarayana S. Pharmacodynamic and pharmacokinetic drug interaction of gliclazide and lacidipine in animal models. Ind J Pharm Educ Res 2008;42:277-282.
21. Satyanarayana S, Eswar Kumar K, Rajasekhar J, Thomas L, Rajanna S, Rajanna B. Influence of aqueous extract of fenugreek-seed powder on the pharmacodynamics and pharmacokinetics of gliclazide in rats and rabbits. Therapy 2007;4:457-463.
22. Rollins DE, Klaassen CD. Biliary excretion of drugs in man. Clin Pharmacokinet 1979;4:368-379.
23. Davis TME, Daly F, Walsh JP, Ilett KF, Beilby JP, Dusci LJ, Barrett PHR. Pharmacokinetics and pharmacodynamics of gliclazide in Caucasians and Australian Aborigines with type 2 diabetes. Br J Clin Pharmacol 2000;49:223-230.
24. Campbell DB, Lavielle R, Nathan C. The mode of action on clinical pharmacology of gliclazide - a review. Diabetes Res Clin Pract 1991;14:S21-S36.
25. Wajchenberg BL, Santomano ATMG, Porrelli RN. Effect of sulfonylurea (gliclazide) treatment on insulin sensitivity and glucose-mediated glucose disposal in patients with non-insulin dependent diabetes mellitus (NIDDM). Diabetes Res Clin Pract 1993;20:147-154.
26. Dilman VM. Development, aging and disease. A new rationale for an intervention. Chur: Harwood Academic Publishers, Churchill, 1994.
27. Shikuma CM, Day LT, Gerschenson M. Insulin resistance in the HIV-infected population: the potential role of mitochondrial dysfunction. Curr Drug Targets Infect Disord 2005;5:255-262.
28. FDA approved draft PI Norvir. In: US Food and Drug Administration [electronic resource] 2008 [accessed 2009 June 25]; available from: URL: http://www.accessdata.fda.gov/drugsatfda-docs/label/2008/020945s022, 020659s042lbl.pdf
29. Lee GA, Mafong DD, Lo JC, et al. Ritonavir acutely induces insulin resistance in healthy normal volunteers. Antivir Ther 2005;10:L6.
30. Noor MA, Seneviratne T, Aweeka FT, et al. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS 2002;16:F1-F8.
31. Lee GA, Aweeka F, Schwarz JM, et al. Single dose lopinavir/ritonavir acutely inhibits insulin-mediated glucose disposal in healthy normal volunteers. Clin Infect Dis 2006;43:658-660.
32. Kumar GN, Rodrigues AD, Buko AM, Denissen JF. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 1996;277:423-431.
33. Belfiore F, Iannello S, Volpicelli G. Insulin sensitivity indices calculated from basal and OGTT-induced insulin, glucose, and FFA levels. Mol Genet Metab 1998;63:134-141.
34. Acosta EP. Pharmacokinetic enhancement of protease inhibitors. J Acquir Immune Defic Syndr 2002;29: S11-S18.
35. Rathbun RC, Rossi DR. Low-dose ritonavir for protease inhibitor pharmacokinetic enhancement. Ann Pharmacother 2002;36:702-706.